Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Reviews Its Portfolio, Driving Speculation It May Sell Diabetes Unit

Executive Summary

During its recent quarterly earnings call, Medtronic CEO Geoff Martha reiterated that the company expects to announce changes over the next year that will help it drive growth and shareholder value. Analysts suspect Medtronic’s struggling diabetes business is probably the top candidate for a sale.

You may also be interested in...



Medtronic’s Med Surg President Speaks On Development Strategy, Recent Deals And Hopes For Future

Bob White, president of Medtronic’s medical surgical portfolio spoke to Medtech Insight about how the company develops innovative products like the Hugo robot, recent deals that carved out businesses, and the biggest opportunities for future growth and innovation.

Medtronic Cuts Away More: Spins Off Patient Monitoring And Respiratory Business

Medtronic announced plans to spin off its patient monitoring and respiratory interventions businesses, which currently provide revenues of over $2bn a year. The company previously signaled plans to make significant changes to its business portfolio.

Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors

The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel